The Role of ERBT Plus Adjuvant Intravesical Induction and Maintenance Chemotherapy for Intermediate-Risk NMIBC

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a prospective, multi-centre randomised trial comparing between ERBT plus 1-year of Ad-MMC, versus ERBT alone, in treating intermediate-risk NMIBC.
Epistemonikos ID: c5d616547275a9eb8040fbff38d1460507814c4a
First added on: Oct 31, 2026